These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1401 related articles for article (PubMed ID: 32471019)
81. A transgene-encoded truncated human epidermal growth factor receptor for depletion of anti- B-cell maturation antigen CAR-T cells. Wang Q; He F; He W; Huang Y; Zeng J; Zi F; Zheng J; Fei Y; Xu J; Song Y; Ye X; Lai R; Ye L; Zhu B Cell Immunol; 2021 May; 363():104342. PubMed ID: 33765541 [TBL] [Abstract][Full Text] [Related]
85. An Overview of CAR T Cell Mediated B Cell Maturation Antigen Therapy. Quazi S Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):e392-e404. PubMed ID: 34992008 [TBL] [Abstract][Full Text] [Related]
86. Novel BCMA-OR-CD38 tandem-dual chimeric antigen receptor T cells robustly control multiple myeloma. Feng Y; Liu X; Li X; Zhou Y; Song Z; Zhang J; Shi B; Wang J Oncoimmunology; 2021; 10(1):1959102. PubMed ID: 34434610 [TBL] [Abstract][Full Text] [Related]
87. Current progress of CAR-T-cell therapy for patients with multiple myeloma. Nakashima T; Kagoya Y Int J Hematol; 2024 Jul; 120(1):15-22. PubMed ID: 38777913 [TBL] [Abstract][Full Text] [Related]
88. BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy. Paul B; Rodriguez C; Usmani SZ Drugs; 2022 Apr; 82(6):613-631. PubMed ID: 35412114 [TBL] [Abstract][Full Text] [Related]
89. Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications. Susanibar Adaniya SP; Cohen AD; Garfall AL Am J Hematol; 2019 May; 94(S1):S28-S33. PubMed ID: 30730071 [TBL] [Abstract][Full Text] [Related]
90. Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen. Timmers M; Roex G; Wang Y; Campillo-Davo D; Van Tendeloo VFI; Chu Y; Berneman ZN; Luo F; Van Acker HH; Anguille S Front Immunol; 2019; 10():1613. PubMed ID: 31379824 [TBL] [Abstract][Full Text] [Related]
91. CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies. Zhang X; Zhang H; Lan H; Wu J; Xiao Y Front Immunol; 2023; 14():1101495. PubMed ID: 36891310 [TBL] [Abstract][Full Text] [Related]
92. Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Schmidts A; Ormhøj M; Choi BD; Taylor AO; Bouffard AA; Scarfò I; Larson RC; Frigault MJ; Gallagher K; Castano AP; Riley LS; Cabral ML; Boroughs AC; Velasco Cárdenas RM; Schamel W; Zhou J; Mackay S; Tai YT; Anderson KC; Maus MV Blood Adv; 2019 Nov; 3(21):3248-3260. PubMed ID: 31698455 [TBL] [Abstract][Full Text] [Related]
94. The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma. Feinberg D; Paul B; Kang Y Cell Immunol; 2019 Nov; 345():103964. PubMed ID: 31492448 [TBL] [Abstract][Full Text] [Related]
95. Treatment of Multiple Myeloma Using Chimeric Antigen Receptor T Cells with Dual Specificity. Globerson Levin A; Rawet Slobodkin M; Waks T; Horn G; Ninio-Many L; Deshet Unger N; Ohayon Y; Suliman S; Cohen Y; Tartakovsky B; Naparstek E; Avivi I; Eshhar Z Cancer Immunol Res; 2020 Dec; 8(12):1485-1495. PubMed ID: 33008840 [TBL] [Abstract][Full Text] [Related]
96. [Targeting BCMA in multiple myeloma using chimeric antigen receptor-engineered T cells]. Zhong MJ; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Wang JX Zhonghua Xue Ye Xue Za Zhi; 2019 Oct; 40(10):804-811. PubMed ID: 31775477 [No Abstract] [Full Text] [Related]
97. Single VHH-directed BCMA CAR-T cells cause remission of relapsed/refractory multiple myeloma. Han L; Zhang JS; Zhou J; Zhou KS; Xu BL; Li LL; Fang BJ; Yin QS; Zhu XH; Zhou H; Wei XD; Su HC; Zhang BX; Wang YN; Xiang B; Gao QL; Song YP Leukemia; 2021 Oct; 35(10):3002-3006. PubMed ID: 34031533 [No Abstract] [Full Text] [Related]
98. Infectious complications in patients with relapsed refractory multiple myeloma after BCMA CAR T-cell therapy. Kambhampati S; Sheng Y; Huang CY; Bylsma S; Lo M; Kennedy V; Natsuhara K; Martin T; Wolf J; Shah N; Wong SW Blood Adv; 2022 Apr; 6(7):2045-2054. PubMed ID: 34543400 [TBL] [Abstract][Full Text] [Related]